(QURE)
NMS – Real Time Price. Currency in USD
14.77
-0.83 (-5.32%)
At close: Mar 27, 2026, 4:00 PM EDT
14.76
-0.01 (-0.07%)
After-hours: Mar 27, 2026, 7:22 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
14.77
-0.83 (-5.32%)
At close: Mar 27, 2026, 4:00 PM EDT
14.76
-0.01 (-0.07%)
After-hours: Mar 27, 2026, 7:22 PM EDT
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Name | Position |
|---|---|
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations Officer |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site |
| Mr. Matthew Craig Kapusta CPA | CEO & Executive Director |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer |
| Date | Type | Document |
|---|---|---|
| 2026-03-02 | 10-K | qure-20251231x10k.htm |
| 2026-01-13 | 8-K | qure-20260113x8k.htm |
| 2026-01-09 | 8-K | qure-20260109x8k.htm |
| 2025-12-04 | 8-K | qure-20251204x8k.htm |
| 2025-11-10 | 8-K | qure-20251110x8k.htm |
| 2025-11-03 | 8-K | qure-20251103x8k.htm |
| 2025-06-30 | S-8 | qure-20250630xs8.htm |
| 2025-06-13 | 8-K | qure-20250611x8k.htm |
| 2025-06-02 | 8-K | tm2516829d1_8k.htm |
| 2025-05-09 | 8-K | qure-20250509x8k.htm |
| Ms. Chiara Elizabeth Russo | Senior Director of Investor Relations |
| Ms. Erin Boyer | Chief People & Culture Officer |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |